Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 5Interviews as Topic 4Early Intervention, Educational 4Cisplatin 4Blood Specimen Collection 4pembrolizumab 3cemiplimab 3atezolizumab 3Radiosurgery 3Methods 3Injections 3Etoposide 3durvalumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiation 2PM 01183 2Observation 2Nivolumab 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × CIMAvax EGF × Clear all
NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Not yet recruiting
29 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡